Although BRAF and NRAS mutations are mutually exclusive in the majority of melanomas, dual pathway signalling is also frequently seen in melanoma through functional loss (deletion, silencing and/or mutation) of the tumour suppressor gene PTEN (Figure 1). The gene discussed is BRAF; the disease is melanoma.